



Edward A. Kesicki, Ph.D.

Dr. Kesicki is co-founder of the not-for-profit Afya World Medicines, which merged with the Infectious Disease Research Institute in 2008. He is actively involved in the work of The Lilly TB Drug Discovery Initiative. He has over 11 years experience in small-molecule drug discovery in the biotech industry.

Prior to Afya, Dr. Kesicki was a senior staff scientist and group leader at ICOS Corporation. He championed hit validation and lead optimization for the Chk1 kinase program which led to a Phase I clinical trial for cancer in December 2006 and will enter Phase II in 2008. He also led teams that discovered preclinical candidates in two other kinase programs. One of these, a PI3-kinase inhibitor, recently entered a phase I clinical trial sponsored by Calistoga Pharmaceuticals, Inc.

Dr. Kesicki is an inventor on more than 20 patents in five target areas and is an author of numerous peer-reviewed articles.

Dr. Kesicki received a B.S. from Stanford University and a Ph.D. in Organic Chemistry from the University of California, San Diego. After postdoctoral work at the University of South Carolina, he joined Prolix Inc., a Seattle-area startup prior to joining Icos in 1997.